Ramantamig
Based on 1 Customer Validation
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma.
For research use only. We do not sell to patients.
- Purity : 95%
- CAS No.: 2988886-91-3
- Molecular Weight:153.279 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
immunoglobulin (H-gamma1-scFvkh_L-lambda2)_scFvkh-G1(h-CH2-CH3)
Species Reactivity
Human
IC50 & Target
CD3E & GPRC5D & TNFRSF17
In Vitro
Ramantamig (72 h) potently induces T-cell-mediated cytotoxicity and activation in BCMA-GPRC5D dual-positive human multiple myeloma cell lines (MM.1S, H929, JIM-3, OPM-2) with sub-nanomolar to low nanomolar EC50 values, but has no effect on dual-negative myeloid cell lines[1].
Ramantamig (72 h) induces potent T-cell-mediated cytotoxicity and activation in H929-WT, H929-BCMA-KO, and H929-GPRC5D-KO human multiple myeloma cell lines, with significantly higher potency against dual-target-expressing H929-WT cells[1].
Ramantamig (48 h) potently induces T-cell-mediated cytotoxicity, T-cell activation, and proinflammatory cytokine production in H929 human multiple myeloma cells spiked into healthy human whole blood, with low nanomolar EC50 values[1].
Ramantamig (48 h) does not induce nonspecific T-cell activation or immune cell cytotoxicity in healthy human purified T cells or whole blood, except at very high concentrations (>10 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BCMA-GPRC5D dual-positive human multiple myeloma cell lines: MM.1S, H929, JIM-3, OPM-2; BCMA-GPRC5D dual-negative cell lines: MV-4-11, OCI-AML-3; pan-T cells from 6 healthy human donors
-
Concentration:dose-dependent (EC50 values reported)
-
Incubation Time:72 h
-
Result:Induced potent cytotoxicity in dual-positive MM cell lines with EC50 values of 0.002 nM (MM.1S), 0.005 nM (H929), 0.312 nM (JIM-3), and 0.019 nM (OPM-2).
Reached maximum cytotoxicity of 92.58% (MM.1S), 94.47% (H929), 61.22% (JIM-3), and 81.32% (OPM-2).
Induced T-cell activation with EC50 values of 0.010 nM (MM.1S), 0.008 nM (H929), 1.070 nM (JIM-3), and 0.062 nM (OPM-2).
Reached maximum T-cell activation of 75.03% (MM.1S), 85.90% (H929), 30.85% (JIM-3), and 45.95% (OPM-2).
Did not induce cytotoxicity or T-cell activation in dual-negative MV-4-11 or OCI-AML-3 cell lines.
In Vivo
Ramantamig (0.025-1 mg/kg; i.p.; twice weekly; 7 doses) induces dose-dependent tumor growth inhibition and complete regression in MM.1S multiple myeloma xenografts, with the 1 mg/kg dose achieving 109% ΔTGI and 100% tumor regression by day 34, and sustaining 100% complete regression by day 51[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (female, aged ~5 to 8 weeks, weighing ~20 g, T-cell-humanized, subcutaneous xenograft of RPMI 8226 cells)[1]
-
Dosage:0.1 mg/kg; 0.4 mg/kg; 1 mg/kg; 2.5 mg/kg
-
Administration:i.p.; twice weekly; 8 doses
-
Result:Induced tumor growth inhibition (ΔTGI) values of 38.4% at 0.1 mg/kg, 90.5% at 0.4 mg/kg, 106.2% (with 51.7% tumor regression) at 1 mg/kg, and 111.2% (with 95.2% tumor regression) at 2.5 mg/kg on day 38.
Achieved complete tumor regression in 2 of 9 mice in the 0.4 mg/kg group, 8 of 10 mice in the 1 mg/kg group, and 9 of 9 mice in the 2.5 mg/kg group by day 60.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (female, aged ~5 to 8 weeks, weighing ~20 g, T-cell-humanized, subcutaneous xenograft of MM.1S cells)[1]
-
Dosage:0.025 mg/kg; 0.1 mg/kg; 0.5 mg/kg; 1 mg/kg
-
Administration:i.p.; twice weekly; 7 doses
-
Result:Induced ΔTGI values of 72.9% at 0.025 mg/kg, 99.4% at 0.1 mg/kg, 108.6% (with 95.9% tumor regression) at 0.5 mg/kg, and 109% (with 100% tumor regression) at 1 mg/kg on day 34.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
half-G1-lambda-scFvkh_scFvkh-h-CH2-CH3
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2988886-91-3
-
Appearance Liquid
-
Molecular Weight 153.279 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
JNJ-79635322; JNJ-5322
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)